StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Raymond James Reiterates Outperform Rating on Johnson & Johnson (JNJ)
January 22, 2025 8:15 AM
Raymond James analyst Jayson Bedford reiterated an Outperform rating and $170.00 price target on Johnson & Johnson (NYSE: JNJ)The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Form 8-K JOHNSON & JOHNSON For: Jan 22
January 22, 2025 6:36 AM
J&J beats quarterly sales and profit estimates on cancer drug sales
January 22, 2025 6:23 AM
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; offers 2025 guidance
January 22, 2025 6:22 AM
Johnson & Johnson Reports Q4 and Full-Year 2024 Results
January 22, 2025 6:20 AM
Johnson & Johnson (JNJ) call put ratio 3.5 calls to 1 put with a focus on January 24 weekly 155 calls into quarter results
January 21, 2025 11:12 AM
Johnson & Johnson (JNJ) Announces SPRAVATO Approved in the U.S.
January 21, 2025 8:05 AM
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
January 21, 2025 8:00 AM
Johnson & Johnson (JNJ) calls more active than puts into quarter results
January 21, 2025 5:38 AM
